U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...